Company Insights

SBCWW customer relationships

Explore interactive graphBrowse insights index
SBCWW customer relationship map

SBC Medical Group Holdings (SBCWW) — Customer Relationships That Drive Revenue and Risk

SBC Medical Group operates as a franchisor and management services provider to cosmetic treatment centers, primarily in Japan, monetizing through long‑term licensing fees, royalty income and comprehensive management contracts that bundle advertising, staffing, procurement and technology services. More than 90% of revenue derives from these management and franchise relationships, producing recurring cash flows tied to the operational health of medical corporations (MCs) that run the clinics. For an institutional view of SBC’s relationship network and contractual posture, visit https://nullexposure.com/.

What the contract architecture says about the business

SBC’s operating model is franchise‑centric and services‑heavy. The 2024 Form 10‑K documents a fabric of multi‑year intellectual‑property and support agreements with MCs that generate franchising (royalty) income and management fees. Key company‑level signals from the filing:

  • Long‑term contracting posture: Support and license agreements run for multi‑year terms with automatic renewals (e.g., 9‑year initial terms with successive two‑year renewals; a PDISPA initially from Sept 2021–Aug 2026 with annual renewals thereafter), which supports predictable recurring revenue and lock‑in.
  • Licensing and franchising as core monetization: The company licenses the “Shonan Beauty Clinic” brand and related IP and collects monthly royalties (fee bands cited in the filing).
  • Geographic concentration with a global footprint: Substantially all long‑lived assets and revenue are attributed to Japan, although operations extend into Vietnam, Singapore and the U.S., indicating APAC concentration with selective global exposure.
  • High materiality and concentration risk: The 10‑K states the company generates more than 90% of revenue from management services to MCs; revenues with related parties in aggregate are reported at roughly $195.2 million in FY2024 — a material revenue dependency.
  • Mixed counterparty composition: The filing treats many MCs as non‑profit medical corporations under Japanese law (governance and profit‑distribution constraints), and separately documents loans and consumer finance activity introduced in 2023 to end customers.

These structural points underline both the durability of cash flow and the concentration risk that investors must price.

The full customer ledger — who SBC lists in its FY2024 10‑K

Below is a concise, one‑to‑two sentence summary for every customer relationship named in SBC’s FY2024 10‑K related‑party schedule. Each entry sources the company’s FY2024 Form 10‑K.

AI Med Inc.

The FY2024 10‑K lists AI Med Inc. in the related‑parties schedule with numerical entries “787” and “556,397” alongside the name, indicating a recorded transactional relationship in FY2024. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Amulet Inc.

Amulet Inc. is recorded in the FY2024 related‑party schedule with the entry “3,587,” reflecting a recorded balance or transaction with the company during the year. (Source: SBC 2024 Form 10‑K, related parties schedule.)

General Incorporated Association SBC

General Incorporated Association SBC appears in the related‑party schedule with numeric entries “801” and “569,” indicating active financial interactions reported in FY2024. (Source: SBC 2024 Form 10‑K, related parties schedule.)

General Incorporated Association Taiseikai

The FY2024 10‑K lists General Incorporated Association Taiseikai with the figure “692,” documenting a related‑party item in the reporting year. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Hariver Inc.

Hariver Inc. is shown with entries “19,810” and “21,740” in the FY2024 related‑party disclosure, signaling recorded transactions or balances with SBC during the year. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Japan Medical & Beauty Inc.

Japan Medical & Beauty Inc. is recorded with entries “39,620” and “488,023” in the FY2024 related‑party schedule, reflecting material recorded amounts tied to the relationship. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Medical Corporation Aikeikai

Medical Corporation Aikeikai appears with large balances “17,997,072” and “21,521,302” in the FY2024 related‑party disclosures, representing significant financial exposure between the parties. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Medical Corporation Association Furinkai

Medical Corporation Association Furinkai is listed with entries “11,708,183” and “2,923,608,” showing substantial recorded amounts in SBC’s FY2024 related‑party schedule. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Medical Corporation Association Junikai

Medical Corporation Association Junikai is shown with “3,923,228” and “851,105” in the FY2024 related‑party list, reflecting transactional balances for the year. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Medical Corporation Jukeikai

Medical Corporation Jukeikai is recorded with entries “5,666,907” and “4,518,846” in SBC’s FY2024 related‑party disclosure. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Medical Corporation Kowakai

Medical Corporation Kowakai appears with very large recorded amounts “46,756,189” and “45,115,149” in the FY2024 related‑party schedule, representing one of the largest single‑entity exposures. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Medical Corporation Nasukai

Medical Corporation Nasukai is listed with “46,355,437” and “45,893,461” in the FY2024 related‑party schedule, showing another material counterparty balance. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Medical Corporation Ritz Cosmetic Surgery

Medical Corporation Ritz Cosmetic Surgery appears with “7,435,446” and “2,603,405” recorded in the FY2024 related‑party disclosures. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Medical Corporation Shobikai

SBC reports Revenues from related parties for Medical Corporation Shobikai of $53,862,520 in 2024 and $56,554,316 in 2023, making Shobikai a material revenue source reported in the 10‑K. (Source: SBC 2024 Form 10‑K, related‑party revenue disclosure.)

Mizuho Yamashita

Mizuho Yamashita is recorded with the entry “19,214” in the FY2024 related‑party schedule, indicating transactional recognition in the year. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Public Utility Foundation SBC Foundation for Medical Promotion

The FY2024 10‑K lists Public Utility Foundation SBC Foundation for Medical Promotion with entries “107” and “387,” showing nominal recorded interactions with this foundation. (Source: SBC 2024 Form 10‑K, related parties schedule.)

SBC Inc., previously known as SBC China Inc.

SBC Inc. (previously SBC China Inc.) is recorded with “2,512” and “467” in the FY2024 related‑party schedule, reflecting intercompany or related‑party balances. (Source: SBC 2024 Form 10‑K, related parties schedule.)

SBC Irvine MC

SBC Irvine MC is shown with entries “1,204,107” and “1,298,539” in the FY2024 related‑party disclosures, representing material balances tied to SBC’s Irvine management entity. (Source: SBC 2024 Form 10‑K, related parties schedule.)

SBC Shonan Osteopathic Clinic Inc.

SBC Shonan Osteopathic Clinic Inc. is listed with “56,740” and “69,227” in the FY2024 related‑party schedule. (Source: SBC 2024 Form 10‑K, related parties schedule.)

SBC Tokyo Medical University (previously Ryotokuji University)

SBC Tokyo Medical University (previously Ryotokuji University) appears with “45,286” and “231,191” recorded in the FY2024 related‑party schedule. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Yoshiyuki Aikawa

The FY2024 10‑K records Yoshiyuki Aikawa with entries “98,445” and “67,516” in the related‑party schedule, indicating personal or executive‑level recorded interactions. (Source: SBC 2024 Form 10‑K, related parties schedule.)

Operational implications for investors

The relationship ledger exhibits two dominant themes: durable, contractual revenue with concentrated counterparties, and meaningful exposure to non‑profit medical corporations governed by Japanese law. Practical investment implications:

  • Revenue predictability is high because of long‑term, auto‑renewing licensing and support agreements; however, concentration risk is also high since a small set of MCs account for the majority of revenue.
  • Counterparty governance constraints matter: MCs that operate under Japanese non‑profit rules cannot distribute profits, which affects SBC’s equity economics and recovery options if an MC underperforms.
  • Credit and operational linkages are expanding: SBC’s 2023 start of loan services to end customers introduces consumer credit exposure and a new counterparty layer (individuals), changing cash‑flow and collection dynamics.
  • Material related‑party balances (aggregate related‑party revenue ~ $195.2 million for 2024) mean any deterioration at a handful of MCs would quickly affect reported revenue and margins.

For portfolio managers and operators needing deeper counterparty analytics, see the SBC relationship hub at https://nullexposure.com/ for structured access to the filings and extracted relationship schedules.

Bottom line — where investors should focus

SBC’s model delivers recurring, franchisor‑style cash flows but concentrates operational and credit risk in a small universe of MCs that together drive the company’s top line. Evaluate SBC through two lenses: (1) contract durability and royalty mechanics that support baseline earnings, and (2) counterparty concentration and regulatory governance of MCs that amplify downside. For structured research and to monitor how these relationships evolve over time, visit https://nullexposure.com/.

Actionable next steps: review SBC’s FY2024 10‑K counterparty schedules for the MCs with the largest balances (Kowakai, Nasukai, Shobikai) and model sensitivity to clinic throughput and royalty renegotiation. For access to the underlying filing extracts and relationship timelines, go to https://nullexposure.com/.